Fevipiprant Anti Hair Loss Powder 99% QAW039 Cas NO 872365-14-5 In Bulk

Place of Origin China
Brand Name XRD
Certification GMP
Model Number 872365-14-5
Minimum Order Quantity negotiable
Price Inquiry for Negotiable
Packaging Details 1-2 kg / aluminum foil bag, 25kg/ drum, as required
Delivery Time 1-2days after payment received
Payment Terms T/T bank, Western Union, Bitcoin, Etc
Supply Ability 100KG/ Month

Contact me for free samples and coupons.

Whatsapp:0086 18588475571

Wechat: 0086 18588475571

Skype: sales10@aixton.com

If you have any concern, we provide 24-hour online help.

x
Product Details
CAS 872365-14-5 Product Name Fevipiprant
Type Loss Hair Appearance White Powder
Usage Loss Hair Alias QAW039
Assay 99% Key Words Fevipiprant
High Light

hair growing powder

,

hair growth powder

Leave a Message
Product Description

Fevipiprant powder 99% QAW039 Cas 872365-14-5 Powder in Bulk

 

 

Quick Details 

Name

 

 

Fevipiprant

Synonyms

QAW 039; [1-(4-((Methane)sulfonyl)-2-trifluoromethylbenzyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]acetic acid

Brand

Salus

Molecular Formula

C19H17F3N2O4S

Molecular Weight

426.41

CAS Registry Number

872365-14-5

 

 

Description: 

 

Fevipiprant is a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). Its ability to extend the anagen (growing) phase of hair follicles. Although this won’t stop androgenic alopecia from progressing further, it will have the short term effect of making hair appear thicker. What’s more, this effect could make Setipiprant an effective treatment for the prevention of telogen effluvium. But perhaps the biggest advantage of Setipiprant is that is expected to have zero anti-androgenic effects.

 

 

Setipiprant (INN) (developmental code names ACT-129,968, KYTH-105) is a drug originally developed by Actelionwhich acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2).[1] It was initially researched as a treatment for allergies and inflammatory disorders, particularly asthma, but despite being well tolerated in clinical trials and showing reasonable efficacy against allergen-induced airway responses in asthmatic patients,[2][3] it failed to show sufficient advantages over existing drugs and was discontinued from further development in this application.

 

 

 

 

High Purity Pharmaceutical Intermediate Pentobarbital Sodium CAS 57-33-0

 

 

Fevipiprant powder 99% QAW039 Cas 872365-14-5 Powder in Bulk